Digital health companies are developing in scale, as greater amounts of venture capital funding enters the sector.
TrialSpark, a technology-focused developer of clinical trials, has utilized this interest to sign another clinical trial partnership agreement with Limbix, which follows shortly on from a similar deal with 23andMe and, prior to that, Pfizer.
The latest collaboration will see the two companies partner to plan and instigate a clinical trial for Limbix Spark, which uses mobile and virtual reality (VR) technology to treat adolescent depression.
Limbix Spark itself is a five-week program that uses cognitive behavioral therapy to help teenagers identify behaviors and activities that can influence their mood positively.
TrialSpark will bring the digital therapeutic to doctors through its clinical trial sites, which can recruit patients to fit enrollment criteria for Limbix’s trial of its technology through the use of anonymized, aggregated data of potential patients.
Jeff Yuan, head of client growth at TrialSpark, commented that the company’s network of community physicians allows direct feedback on trials, as well as allowing the digital therapeutic to reach “diverse geographies” that would usually not gain access to such treatments.
